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Background: The Stroke Oxygen Study (SO2S) is a multi-center randomized controlled trial of oxygen supplementation
in patients with acute stroke. The main hypothesis for the trial is that fixed-dose oxygen treatment during the first
3 days after an acute stroke improves outcome. The secondary hypothesis is that restricting oxygen supplementation
to night time only is more effective than continuous supplementation. This paper describes the statistical analysis plan
for the study.
Methods and design: Patients (n = 8000) are randomized to three groups: (1) continuous oxygen supplementation
for 72 hours; (2) nocturnal oxygen supplementation for three nights; and (3) no routine oxygen supplementation.
Outcomes are recorded at 7 days, 90 days, 6 months, and 12 months. The primary outcome measure is the modified
Rankin scale at 90 days. Data will be analyzed according to the intention-to-treat principle. Methods of statistical
analysis are described, including the handling of missing data, the covariates used in adjusted analyses, planned
subgroups analyses, and planned sensitivity analyses.
Trial registration: This trial is registered with the ISRCTN register, number ISRCTN52416964 (30 September 2005).
Keywords: hypoxia, oxygen supplementation, randomized controlled trial, statistical analysis plan, strokeBackground
Whilst it is generally acknowledged that specialist care
on stroke units is effective in preventing death and dis-
ability after stroke [1], it is not known which aspects of
stroke care are crucial in this respect. Mild hypoxia
commonly occurs in stroke patients and hypoxemia in
the first few hours after admission to hospital admission
is associated with an increased risk of death [2]. Guid-
ance for oxygen treatment after stroke differs between
countries, and is not based on evidence from random-
ized controlled trials. In many accident and emergency
departments in the UK, oxygen is given routinely to
stroke patients regardless of blood oxygen levels. In* Correspondence: j.sim@keele.ac.uk
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unless otherwise stated.support of the use of oxygen is evidence that eubaric
hyperoxia may be neuroprotective [3,4]. However, there
is also evidence that oxygen encourages the formation of
toxic free radicals, leading to further damage to the is-
chemic brain [5-8]. Additionally, the tubing used to de-
liver oxygen impedes mobilization and may pose a risk
of infection. A study of eubaric hyperoxia using ex-
tremely high-flow oxygen supplementation (45 l/min)
for 8 hours was abandoned in 2009 because of increased
mortality in the oxygen group (Singhal et al., unpub-
lished work: http://www.clinicaltrials.gov).
Patients are more likely to be hypoxic at night [9,10],
hypoxia is more likely to be missed at this time, and
nocturnal hypoxemia carries a greater risk of brain tissue
hypoxia [11]. Nocturnal oxygen supplementation does
not interfere with the patient’s daytime mobility and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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routine oxygen only at night might therefore prevent a
significant number of otherwise undetected episodes of
hypoxia without interfering with the patient’s daytime
rehabilitation.
The Stroke Oxygen Study (SO2S) evaluated the use of
low-dose oxygen therapy in the first 72 hours following
stroke [13]. The aim of this study is, firstly, to assess
whether patients benefit from oxygen after stroke, and
secondly to establish whether nocturnal oxygen supple-
mentation is more effective than continuous oxygen sup-
plementation. Fuller details of the rationale and the
design the study are given in the study protocol; this
paper describes the statistical analyses to be undertaken
on the study data. It should be read in conjunction with
the protocol [13].Study design
The Stroke Oxygen Study is a multi-center randomized
controlled trial of oxygen supplementation in patients
with acute stroke.
Patients are randomized in a ratio of 1:1:1 to three groups:
(1) continuous oxygen supplementation for 72 hours; (2)
nocturnal oxygen supplementation for 3 nights; and (3)
no routine oxygen supplementation. Oxygen is given at
a rate of 2 to 3 l/min, depending on baseline oxygen satur-
ation. Randomization is conducted via a web-based inter-
face using minimization. The minimization variables are:
(1) the ‘six simple variables’ (SSV) score for being alive
and independent at 6 months (derived from age, and yes/
no scores for: living alone, pre-stroke independence in ac-
tivities of daily living, normal speech, ability to lift both
arms, ability to walk) [14,15], with the cut-offs <0.1, >0.1
to ≤0.35, >0.35 to ≤0.70, and >0.70; (2) oxygen given in
the ambulance or hospital prior to randomization (yes, no,
or unknown); (3) oxygen saturation on room air at
randomization (<95 and ≥95%); and (4) time since stroke
onset (≤3, >3 to ≤6, >6 to ≤12, >12 to ≤24 and >24 hours).
Patients are followed up at 7 days, 90 days, 180 days, and
1 year [13].
Multi-center ethical approval was granted for SO2S by
the North Staffordshire Research Ethics Committee on 25
June 2008 (COREC 06/Q2604/109). Informed consent
was obtained from each participant in the study [13].Main hypothesis
Fixed-dose oxygen treatment during the first 3 days after
an acute stroke improves outcome.Secondary hypothesis
Restricting oxygen supplementation to night time only is
more effective than continuous supplementation.Sample size
The original sample size for the study was 6,000 partici-
pants. This would detect an odds ratio of 0.83 for a one-
point difference in the modified Rankin scale (mRS)
score in a comparison of the combined oxygen supple-
mentation groups and the control group, assuming 95%
power and a 5% two-tailed significance level. With allow-
ance for 10% loss to follow-up, this gave a recruitment tar-
get of 6,669. The recruitment target was subsequently
revised in October 2012 to 8,000 patients, to provide
greater power to detect an interaction between subgroups
(defined by severity) and the effect of oxygen versus con-
trol; see the study protocol [13].
General considerations
Levels of confidence and P values
Unless otherwise specified, estimates of treatment effects
will be presented with 95% confidence intervals. A two-
tailed P value of ≤0.05 will be considered statistically sig-
nificant for the primary outcome measure. For the analysis
of secondary outcomes, a two-tailed P value of ≤0.01 will
be considered statistically significant and estimates will be
presented with 99% confidence intervals.
Protocol violations and exclusions from the study
Analysis will be according to the intention-to-treat
principle, meaning that all patients will be analyzed in
the treatment arm to which they were randomized, and
all patients will be included, whether or not they re-
ceived the allocated treatment. Protocol deviations and
exclusions (and reasons for any such exclusions) will be
reported for each arm of the trial.
Unadjusted and adjusted analyses
For each outcome variable, the unadjusted analysis will
be designated the primary analysis; the covariate-adjusted
analysis will be designated the secondary analysis. Ad-
justed analyses will incorporate the following covariates:
age, sex, baseline National Institutes of Health Stroke
Scale (NIHSS) score [16], baseline oxygen saturation, the
SSV prognostic index for 6-month independence (for
analysis of mortality data, the prognostic index for 30-
day survival will be used in place of that for six-month
independence).
Missing data
Every effort will be made to obtain missing data, even after
the follow-up time has passed. Patients who are contact-
able at 6 months, but have not completed the 3-month
questionnaire, will be asked to think back to 3 months
and consider for each missing data point what they were
like at that time. Where it is impossible to get any infor-
mation from the patients or friends or family members
designated by the patients as alternative contacts, we will
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tors at the hospital where they were admitted to deter-
mine whether there is information on record (such as
discharge letters or clinic letters that provide information
on the patient’s status at or near the time of the missing
assessment). Some of the information on the question-
naires is duplicated; that is, items measuring a particular
variable exist in more than one questionnaire. Where such
information is provided in one questionnaire but omitted
in another, the relevant data will be used to complete the
missing data, where possible.
Missing data that remain following such efforts will be
estimated through multiple imputation. The main ana-
lyses will be based on available data only (including in-
formation secured by the strategies described above).
Analyses based on imputed data will be reported as part
of the sensitivity analyses (described later).Interim analyses and stopping rules
Interim analyses of efficacy and safety for the data safety
and monitoring committee are planned annually. These
analyses will be considered in the closed session of the
committee. The committee will advise the chair of the
trial steering committee if, in their view, the randomized
comparisons in the trial have provided both (a) ‘proof
beyond reasonable doubt’ that for all, or for some types
of, patients one particular treatment is definitely indi-
cated or definitely contraindicated in terms of a net dif-
ference in the major endpoints, and (b) evidence that
might reasonably be expected to influence patient man-
agement by many clinicians who are already aware of
the other main trial results. Appropriate criteria for
proof beyond reasonable doubt are not specified pre-
cisely, but an effect equivalent to a difference of at least
three standard deviations in an interim analysis of a
major endpoint might be seen as a reasonable justifica-
tion for modifying the protocol or for halting the study
prematurely.Start of data analysis
The first analysis of the main trial data for publication
purposes will begin once the final randomized patient
has reached the 90-day follow-up and missing data have
been chased. We will aim to achieve at least 95% follow-
up rates for the main outcome. The database will be fro-
zen and the statistical analysis plan agreed before any
analysis is carried out.
The second analysis of the main trial data for publica-
tion purposes will begin once the final randomized pa-
tient has reached the 12-month follow-up, using the
same procedures. We will again aim for >95% returns
for the main outcome, but will accept >90% if this is not
achieved within 3 months of the last due response.Proposed analyses
Treatment comparisons
Two distinct treatment comparisons are planned in this
study. The first is to compare oxygen supplementation
with no oxygen supplementation (with the former group
comprising both patients who were allocated nocturnal
oxygen only for three nights and patients allocated con-
tinuous oxygen for 72 hours). The second comparison
compares the two oxygen supplementation groups with
each other (nocturnal oxygen only for three nights ver-
sus continuous oxygen for 72 hours).
In addition to the two main comparisons, in the event
that, in relation to the primary outcome measure, (a) the
overall comparison between both oxygen supplementa-
tion groups and the control group is non-significant, but
(b) one oxygen supplementation group shows signifi-
cantly greater benefit than the other, a comparison will
be performed (on the primary outcome measure only)
between the better of the two oxygen supplementation
groups and the control group. This is to examine the
possibility that, for example, nocturnal oxygen supple-
mentation may have a beneficial effect that is offset by,
and thus masked by, a non-beneficial or harmful effect
of continuous oxygen supplementation.
The analyses described next will be repeated for each
of the two main comparisons.
Primary outcome measure
The primary outcome measure is the modified Rankin
scale (mRS) at 90 days after randomization [17]. The
mRS is an ordinal scale ranging from 0 (no disability) to
5 (extreme disability). Patients who die prior to the 90-
day time point will be considered to have an mRS score
of 6, thus creating a 0 to 6 scale.
The mRS will be analyzed using an ordinal logistic re-
gression model. Both an unadjusted (primary) and ad-
justed (secondary) analysis will be performed using the
covariates specified earlier (see General considerations
section).
Secondary outcome measures at 7 days
Secondary outcome measures at 7 days comprise: the
NIHSS; the number of patients with neurological im-
provement (≥4 point decrease from baseline or a value
of 0 in the NIHSS); mortality; highest oxygen saturation
during the first 72 hours; lowest oxygen saturation dur-
ing the first 72 hours; the number of patients whose oxy-
gen saturation falls below 90%.
Secondary outcome measures at 90 days
Secondary outcome measures at 90 days comprise: mor-
tality; the number of patients alive and independent
(mRS ≤2); the number of patients living at home; ability
to perform activities of daily using (using the Barthel
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the EuroQoL EQ-5D questionnaire [19]); extended activ-
ities of daily living (using the Nottingham Extended Activ-
ities of Daily Living (NEADL) index [20]).
Participants who die before the assessment point will
not have data for the NIHSS, Barthel index, EuroQol
EQ-5D, or NEADL index. This could bias results in
favor of the treatment arm with higher mortality. Death
will therefore be included in the analysis of the NIHSS,
EuroQol EQ-5D, and NEADL index as the worst out-
come on the scale [21].
For numerical outcomes, means and standard deviations
or medians and interquartile ranges will be reported, as
appropriate. Unadjusted analyses will use an unrelated t
test, with the mean difference between treatments and ap-
propriate confidence interval reported. In the event of
major deviations from the assumptions of the t test, an ap-
propriate alternative analysis will be used. The adjusted
analysis will use analysis of covariance methods, with the
covariates specified earlier included in the analysis.
For dichotomous outcomes, percentages will be com-
pared across the treatment comparisons using a χ-squared
or Fisher exact test as appropriate for the unadjusted ana-
lysis. The adjusted analysis of dichotomous outcomes will
use binary logistic regression, using the covariates listed
earlier. Odds ratios and confidence intervals will be re-
ported. The number needed to be treated will also be cal-
culated [22].
For ordinal secondary outcomes, the analyses described
for the mRS will be applied.
Data at 6 and 12 months
The longer-term follow-up data at 6 and 12 months will
be analyzed at each time point using the same methods
described earlier. In addition, analyses will be performed
across 3-, 6- and 12-month time points using a longitu-
dinal repeated measures analysis, such as linear mixed
models [23].
The treatment effect will initially be assumed to be
constant over time; further analyses may be carried out
to investigate the effects of including time and a treat-
ment × time interaction in the models.
Mortality will be analyzed using log-rank methods
(unadjusted analysis) with Kaplan-Meier plots presented.
The adjusted analysis will use Cox regression methods,
including the covariates listed previously. In the covari-
ates, the prognostic index for 30-day survival will replace
that for independence at 6 months. The proportional
hazards assumption associated with the Cox regression
model will be tested via Schoenfeld residuals (this as-
sumption was found to be tenable in the analysis of the
6-month survival in the pilot study [24]). Hazard ratios
and 99% confidence intervals will be reported for both
unadjusted and adjusted analyses.Planned subgroup analyses
These will be performed in respect of the primary out-
come measure only, based on a risk-stratification ap-
proach [25]. The subgroups comprise: NIHSS score at
baseline as indicator of stroke severity (0 to 4, 5 to 9, 10
to 14, 15 to 20, >20); baseline% oxygen saturation (<92,
92 to 93.9, 94 to 94.9, 95 to 97, >97); treatment with O2
prior to randomization (yes or no); time in hours since
onset of stroke (≤3, >3 to 6, >6 to 12, >12 to 24, >24);
type of stroke (hemorrhage or infarct); Glasgow Coma
Scale motor score plus eye score (<10, 10); age (<50, 50
to 80, >80); history of chronic obstructive airways disease
or asthma (yes or no); history of heart failure (yes or no);
thrombolysis (yes or no); baseline SSV risk score for in-
dependence at 6 months (≤0.1, >0.1 and ≤0.35, >0.35
and ≤0.7, >0.7).
These subgroup effects will be analyzed by means of
an interaction term [26]; however, pairwise hypothesis
tests between the levels of the subgroup factor will not
be performed, owing to the probably low level of statis-
tical power. Subgroup-specific estimates will be reported
descriptively with 95% confidence intervals and displayed
graphically in a forest plot, and will be interpreted with
caution (especially in respect of any subgroups with low
numbers).Exploratory analyses
Exploratory analyses will be conducted using data col-
lected at 7 days. These will include details of the stroke
diagnosis and imaging (for example, imaging results,
final diagnosis, stroke syndrome [27], etiological classifica-
tion [28], indicators of compliance with the trial treatment,
oxygen saturation during the intervention), and clinical data
that might indicate stress induced by the intervention, for
example, sedative use, the number of participants whose
highest heart rate was >100 beats per minute, whose high-
est systolic blood pressure was >200 mmHg, or whose
highest diastolic blood pressure was >100 mmHg during
the intervention, or who developed infections (antibiotic
use during the first 7 days).
In addition, we will report data on symptoms that
were highlighted as important for their quality of life by
stroke patients and their carers [29], but not sufficiently
covered in the validated tools used for the assessment of
the primary and secondary outcomes. These are: the
number of patients who reported their memory, eye-
sight, and sleep as being ‘as good as before the stroke’,
and the number who reported that they had no signifi-
cant speech problems (no problems or some problems
but not interfering significantly with conversation).
These outcomes were adapted from the ‘simple ques-
tions’ described by Lindley et al. [30], but are not
validated.
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across the treatment comparisons at each time point,
but will not be subjected to formal statistical testing.
Sensitivity analyses
The following sensitivity analyses will be performed.
Two comparative analyses with the observed case ana-
lysis will be performed to allow for missing data. First, a
multiple imputation method, using at least ten imputed
datasets, will be used. These imputations will be based
on specified baseline covariates (age, sex, treatment
group, oxygen saturation, SSV risk score, NIHSS score)
and values of the outcome variable concerned at other
time points. If necessary, missing data on baseline covar-
iates used in the multiple imputation algorithm will be
estimated [31]. Second, two additional imputations will
be conducted to allow for the possibility that data is
missing not at random, and missing values are (i) better
or (ii) worse than would otherwise be expected.
Two comparative analyses with the intention-to-treat
analysis will be performed [32]. First, a per-protocol
‘adherers only’ analysis will be conducted, where only
patients who complied with treatment are analyzed. Sec-
ond, a per-protocol ‘as treated’ analysis (if feasible) will
be carried out, where patients are classified with respect
to the intervention that they ultimately received rather
than the intervention to which they were randomized.
Additionally, in the event that the proportional odds
assumption for analysis of the main outcome does not
hold, an appropriate alternative method will be investi-
gated, such as a sliding dichotomy analysis [33].
Serious adverse events
The proportion of patients who experience at least one
serious adverse event will be analyzed as a categorical
variable (with patients classified as either having experi-
enced at least one serious adverse event, or not) using a
χ-squared or Fisher’s exact test (as appropriate). If ap-
propriate, a more complex model of serious adverse
event occurrences will be constructed utilizing adverse
events as count variables. Possible models for this ana-
lysis include Poisson regression and negative binomial
regression. An analysis of subgroups of serious adverse
events will be performed separately, but in an identical
manner to the overall adverse events analyses.
Health economic analyses
As indicated in the trial protocol [13], there will also be
an economic analysis. The details of this analysis are
documented separately.
Status
The final version of this statistical analysis plan was ap-
proved by the trial steering committee on 4 March 2014.Abbreviations
mRS: modified Rankin scale; NEADL: Nottingham Extended Activities of Daily
Living; NIHSS: National Institutes of Health Stroke Scale; SO2S: Stroke Oxygen
Study; SSV: six simple variables.
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